As the LE multigene panel was derived based on its association with CNTN1 in PC, the observed biomarker potential of the LE gene panel in assessing both poor OS in ccRCC and in predicting PC relapse risk is intriguing. The gene discussed is CNTN1; the disease is nonpapillary renal cell carcinoma.